

## Hi Torque Connect Guidewire - 510(k)

# 510(k) Summary – Hi Torque Connect Guidewires Traditional 510(k)

<del></del>						
Device Name	Hi Torque Guidewire					
Submitters name	Lake Region Medical Limited, Butlersland,					
	New Ross,					
	Co. Wexford,					
	Ireland.					
Application	Kenneth Walsh					
Correspondent	Senior QA/RA Engineer					
	Brivant Ltd, t/a Lake Region Medical International R&D Centre					
	Tel: +353 91 385037					
	Fax: +353 91 766598					
Summary	12 <sup>th</sup> August 2011		<u>.</u>	<del></del>		
Preparation Date						
Device Name &	Trade Name:	Hi Torque Connect Guide	wire			
Classification	Common Name:	Guidewire				
	Classification Name:	Catheter, Guidewire				
	Device Classification:	Class II, 21 CFR §870.1330	ס			
	Product Code:	DQX				
Intended Use	Intended Use:		<u> </u>			
	Hi-Torque guide wires are indicated to facilitate the placement of percutaneous devices during Percutaneous Transluminal Angioplasty (PTA) in peripheral					
	arteries such as femoral, popliteal and infra-popliteal arteries. This guide wire may also be used with compatible stent devices during therapeutic procedures.					
	may also be used with	compatible stellt devices di	aring therapeut	ic procedures.		
	Contraindications:					
	Hi-Torque wires are not intended for use in the coronary and cerebral					
	vasculature or in patie	nts judged not acceptable fo	or percutaneou	s intervention.		
Device Description	The Hi-Torque Connect guidewire range are disposable medical devices designed					
	for single use only. They consist of a PTFE coated 0.018" diameter stainless steel					
	core wire, one end of which is reduced in diameter in a progressive fashion					
	through a centreless grinding operation. The profile of this reduced section					
	affords the product a reduced area of stiffness and is varied to produce 3 unique					
	levels of support. Each of these 3 levels of support are provided in 3 different					
	length options (145cm – 300cm)					
Predicate Devices	Mar	ufacturer	510k	Date		
	Boston Scientific, V-1	8	K033742	12 <sup>th</sup> Jan 2004		
	Asahi, Treasure		K061984	05 <sup>th</sup> Oct 2006		
	Asahi, Astato 30		K071721	13 <sup>th</sup> July 2007		
	7.5411,7151415-50		1			

Principle of Operation The Hi-Torque Connect guidewire is operated manually by a manual process



#### Hi Torque Connect Guidewire - 510(k)

#### Comparison of Technological Characteristics

The technological characteristics are substantially equivalent to the predicate devices. These performance properties include:

- Same length range provided
- Same diameter (0.018")
- All devices are constructed with a stainless steel core which is reduced in diameter at the distal end to provide flexibility
- The proposed 3 models have equivalent tip stiffness characteristics to the predicate devices.
- All devices have a hydrophilic coating at the distal tip
- All devices have a PTFE coating on the guidewire shaft
- All devices are sterilized using ETO gas

#### Performance Testing (nonclinical)

In vitro bench tests were carried out to demonstrate equivalence with reference to the FDAs guidance document "Coronary and Cerebrovascular Guidewire Guidance, Jan 1995".

The following bench tests were performed:

- Tensile Strength
- Torque Strength
- Outer Diameter measurement
- Torque Response
- Catheter Compatibility
- Coating Adherence/Coating Integrity
- Particulate Testing
- Tip Flexibility

The results from these performance evaluations demonstrated that the Hi-Torque Connect Guidewire range met the acceptance criteria defined in the product specification and performed comparably to the predicate device(s).

Biological Safety of the device has been established through biocompatibility testing carried out in compliance with ISO 10993-1.

The following biocompatibility tests were performed

Test Description	Test Method
Cytotoxicity Study	Qualitative Evaluation – Dye Exclusion &
	Microscopial Evaluation
Cytotoxicity Study	Quantitative Evaluation - MTT or XTT Assay
Irritation Test	Intracutaneous Injection (ISO10993-10)
Sensitisation Test	Kligman Maximisation (ISO10993-10)
Acute Systemic Toxicity Test	Systemic Injection
•	ISO10993-11
Acute Systemic Toxicity Test	ISO-Rabbit-Pyrogen
Haemocompatibility Test	Haematology: Haemolysis – rabbit blood – Direct
	(Complete ASTM Method)
Haemocompatibility Test	Haematology:
	In-vitro Haemocompatiblity Assay
Haemocompatibility Test	Coagulation: The Prothrombin Time Assay (PT)
Haemocompatibility Test	Coagulation: The Unactivated Partial
	Thromboplastin Time Assay (UPTT)



## Hi Torque Connect Guidewire - 510(k)

	Haemocompatibility Test	Thrombosis: In Vivo Thrombogenicity in Dogs	
	Haemocompatibility Test	Complement Activation	
	Haemocompatibility Test	Lee& White Coagulation Assay	
Conclusions	Based on safety and performance testing, technological characteristics and the indications for use for the device, the Hi-Torque Connect Guidewire has been		
	demonstrated to be appropriate for its intended use and is considered to be substantially equivalent to the predicate devices.		



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

NOV - 3 2011

Lake Region Medical Limited c/o Kenneth Walsh Senior QA/RA Engineer Brivant Limited Lake Region Medical International R&D Center Parkmore West Business Galway, Ireland

Re: K112381

Trade/Device Name: Hi Torque Connect Guidewire

Regulation Number: 21 CFR 870.1330 Regulation Name: Catheter Guide Wire

Regulatory Class: Class II Product Code: DQX Dated: July 21, 2011 Received: August 17, 2011

Dear Mr. Walsh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. However, we remind you that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

### Page 2 – Mr. Kenneth Walsh

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours;

Bram Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure



## **Indications for Use Statement**

510(k) Number (if known):	K11238

**Device Name:** 

HI TORQUE GUIDEWIRE

Indications for Use:

Hi-Torque guide wires are indicated to facilitate the placement of percutaneous devices during Percutaneous Transluminal Angioplasty (PTA) in peripheral arteries such as femoral, popliteal and infra-popliteal arteries. This guide wire may also be used with compatible stent devices during therapeutic procedures.

**Contraindications:** 

Hi-Torque wires are not intended for use in the coronary and cerebral vasculature or in patients judged not acceptable for percutaneous intervention.

(Division Sign-C

Division of Carc

510(k) Number

K11239